A Ruthenium-Containing Organometallic Compound Reduces Tumor Growth through Induction of the Endoplasmic Reticulum Stress Gene CHOP
- Type de publi. : Article dans une revue
- Date de publi. : 01/07/2009
-
Auteurs :
Xiangjun MengMili LeyvaMarjorie JennyIsabelle GrossSamir BenosmanBastien FrickerSébastien HarleppPascal HebraudA. BoosPauline WlosikPierre BischoffClaude SirlinMichel PfefferJean-Philippe LoefflerChristian Gaiddon
-
Organismes :
Laboratoire de signalisation moléculaire et neurodégénerescence
Institut de Chimie de Strasbourg
Laboratoire de signalisation moléculaire et neurodégénerescence
De l'homéostasie tissulaire au cancer et à l'inflammation
Laboratoire de signalisation moléculaire et neurodégénerescence
Laboratoire de signalisation moléculaire et neurodégénerescence
Institut de Physique et Chimie des Matériaux de Strasbourg
Institut de Physique et Chimie des Matériaux de Strasbourg
Département Sciences Analytiques et Interactions Ioniques et Biomoléculaires
Laboratoire de signalisation moléculaire et neurodégénerescence
Progression tumorale et microenvironnement. Approches translationnelles et épidémiologie
Institut de Chimie de Strasbourg
Institut de Chimie de Strasbourg
Laboratoire de signalisation moléculaire et neurodégénerescence
Laboratoire de signalisation moléculaire et neurodégénerescence
- Publié dans Cancer Research le 29/10/2020
Résumé : Cisplatin-derived anticancer therapy has been used for three decades despite its side effects. Other types of organometallic complexes, namely, some ruthenium-derived compounds (RDC), which would display cytotoxicity through different modes of action, might represent alternative therapeutic agents. We have studied both in vitro and in vivo the biological properties of RDC11, one of the most active compounds of a new class of RDCs that contain a covalent bond between the ruthenium atom and a carbon. We showed that RDC11 inhibited the growth of various tumors implanted in mice more efficiently than cisplatin. Importantly, in striking contrast with cisplatin, RDC11 did not cause severe side effects on the liver, kidneys, or the neuronal sensory system. We analyzed the mode of action of RDC11 and showed that RDC11 interacted poorly with DNA and induced only limited DNA damages compared with cisplatin, suggesting alternative transduction pathways. Indeed, we found that target genes of the endoplasmic reticulum stress pathway, such as Bip, XBP1, PDI, and CHOP, were activated in RDC11-treated cells. Induction of the transcription factor CHOP, a crucial mediator of endoplasmic reticulum stress apoptosis, was also confirmed in tumors treated with RDC11. Activation of CHOP led to the expression of several of its target genes, including proapoptotic genes. In addition, the silencing of CHOP by RNA interference significantly reduced the cytotoxicity of RDC11. Altogether, our results led us to conclude that RDC11 acts by an atypical pathway involving CHOP and endoplasmic reticulum stress, and thus might provide an interesting alternative for anticancer therapy.
Fichiers liés :
5458.full.pdf
Source